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There is a known chance of reactivation of a previous hepatitis B
virus (HBV) infection in patients undergoing chemotherapy or
immunosuppressive therapy for malignancies, particularly lym-
phomas. These patients may experience direct liver-related
complications or reduced survival because of alterations or
cessation of chemotherapy. Lamivudine, the ﬁrst nucleoside
analog, was developed for the treatment of chronic hepatitis B
and has been shown to be effective in inhibiting viral replication
and decreasing viral load. Various strategies to prevent viral
replication have been proposed in patients with hepatitis B
undergoing chemotherapy.1–3 Earlier use of lamivudine, before
overt clinical hepatitis, has been suggested as the most effective
approach. Use of prophylactic lamivudine can decrease the
incidence of HBV reactivation from 30–80% to 0–17%.1–3 However,
relapse of hepatitis associated with the emergence of lamivudine-
resistant viral strains has proven to limit the long-term efﬁcacy.4–6
The incidence of resistance has been reported as approximately
20% annually.4–6 Entecavir, a deoxyguanosine analog, offers several
advantages over lamivudine for the treatment of HBV reactivation
following chemotherapy. Entecavir exhibits potent antiviral
activity, with a 50% effective concentration more than 300-fold
greater than that of lamivudine and a low resistance rate.7,8 We
describe herein the cases of two patients undergoing chemother-
apy for lymphoma with prophylactic use of entecavir.
The ﬁrst casewas a 62-year-oldwoman treatedwith six courses
of rituximab–cyclophosphamide–doxorubicine–vincristine–pre-
donisolone (R-CHOP) therapy for follicular lymphoma. Pretreat-
ment screening for HBV serology displayed the following pattern:
hepatitis B surface antigen (HBsAg)-positive (1398.2 COI); anti-
hepatitis B core antibody (anti-HBc)-positive; anti-hepatitis B
surface antibody (anti-HBs)-negative; hepatitis B envelope antigen
(HBeAg)-negative; anti-hepatitis B envelope antibody (anti-HBe)-
positive; and HBV DNA not detectable by real-time detection PCR
(RTD-PCR) based on Taq Man chemistry. HBV serology status was
ﬁrst noted at this time. The patient was subsequently started on
21-day interval R-CHOP therapy along with entecavir (0.5 mg/
day). After six cycles of R-CHOP therapy, rituximab maintenance
therapy once per week for four weeks was administered every six
months. Although entecavir was continued until the last follow-up
evaluation 18 months after starting chemotherapy due to
concurrent rituximab maintenance therapy, aminotransferase
levels remained normal and HBV serology status was unchanged.
The RTD-PCR level of HBV DNA also remained below the
quantitation limit.
The second case was a 62-year-old man treated with three
courses of R-CHOP therapy, rituximab monotherapy, and ﬂudar-
abine monotherapy for mantle cell lymphoma. Pretreatment
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HBeAg-positive (168.8 COI); anti-HBe-negative; and detectable
RTD-PCR levels of HBV DNA (4.6 log copies/ml). HBV serology
status was ﬁrst noted at this time. The patient was also started on
chemotherapy and entecavir (0.5 mg/day). After twomonths, RTD-
PCR levels of HBV DNA were below the quantitation limit.
Entecavir was stopped six months after the end of chemotherapy
(20 months after starting chemotherapy). Aminotransferase levels
remained normal, and the RTD-PCR levels of HBV DNA also
remained below the quantitation limit until the last follow-up
evaluation two years after starting chemotherapy.
These observations represent the ﬁrst reports of entecavir use
as a ﬁrst-line drug for prophylaxis against HBV reactivation
following chemotherapy for lymphoma. Although entecavir
showed strong antiviral effects with a low resistance rate, the
risk of genotypic resistance to entecavir has recently been
reported, particularly among patients with preexisting lamivu-
dine-resistant genotypic changes within the reverse transcriptase
domain of HBV polymerase. Tenney et al. reported rates of
entecavir resistance associated with virological breakthrough in
lamivudine-refractory HBV patients of 1% and 9% after one and two
years, respectively.9 Moreover, cumulative four-year resistance
rates of approximately 40% and three-year resistance rates of 29%
in lamivudine-refractory patients have also been reported.10,11
This suggests that prophylactic entecavir may be better proposed
as a ﬁrst-line preventive therapy in chronic hepatitis or inactive
carriers of HBV (i.e., HBsAg-positive patients), rather than as a
rescue therapy in patients presenting viral breakthrough under
lamivudine.
Despite the potential beneﬁts of the prophylactic use of
entecavir, careful clinical monitoring is still required. Moreover,
for patients with lymphoma who are receiving chemotherapy, no
consensus has been reached regarding the optimal duration of
entecavir or lamivudine therapies.
In conclusion, entecavir appears to represent a promising drug
for ﬁrst-line prophylaxis against HBV reactivation in patients
undergoing chemotherapy for hematological malignancies.
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